Study Focus:

ASCEND is a global, five-protocol, phase III program, evaluating the impact of daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, on the hemoglobin levels of anemia patients with chronic kidney disease (CKD) and time to the first occurrence of a major adverse cardiovascular events (MACE)...

Study Population:
10,300 patients with chronic kidney disease across 900 sites in 42 countries

Clinical Events Classification Insight:
Over 7,000 events to be adjudicated between Duke Clinical Research Institute and George Clinical, including major adverse cardiac events such as non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure, and thromboembolic events, as well as venous thromboembolism (VTE), and the progression of CKD.